122 related articles for article (PubMed ID: 30973978)
1. Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients.
Srinivasan M; Chaturvedula A; Fossler MJ; Patil A; Gota V; Prabhash K
J Clin Pharmacol; 2019 Sep; 59(9):1216-1224. PubMed ID: 30973978
[TBL] [Abstract][Full Text] [Related]
2. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.
Ouellet D; Periclou AP; Johnson RD; Woodworth JR; Lalonde RL
Cancer Chemother Pharmacol; 2000; 46(3):227-34. PubMed ID: 11021740
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis.
de Rouw N; Croes S; Posthuma R; Agterhuis DE; Schoenmaekers JJAO; Derijks HJ; Burger DM; Dingemans AM; Ter Heine R
Lung Cancer; 2019 Apr; 130():156-158. PubMed ID: 30885337
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study.
Visser S; Koolen SLW; de Bruijn P; Belderbos HNA; Cornelissen R; Mathijssen RHJ; Stricker BH; Aerts JGJV
Eur J Cancer; 2019 Nov; 121():64-73. PubMed ID: 31561135
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer.
Kavathiya K; Gurjar M; Patil A; Naik M; Noronha V; Joshi A; Gota V; Prabhash K
Clin Pharmacol Drug Dev; 2017 May; 6(3):234-239. PubMed ID: 28371303
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.
Ishibashi T; Yano Y; Oguma T
Br J Clin Pharmacol; 2003 Aug; 56(2):205-13. PubMed ID: 12895194
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ
Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of gentamicin in patients with cancer.
Rosario MC; Thomson AH; Jodrell DI; Sharp CA; Elliott HL
Br J Clin Pharmacol; 1998 Sep; 46(3):229-36. PubMed ID: 9764963
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder.
Agbo F; Bui KH; Zhou D
J Clin Pharm Ther; 2017 Oct; 42(5):539-546. PubMed ID: 28474366
[TBL] [Abstract][Full Text] [Related]
12. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
13. Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
Honoré PH; Joensen SJ; Olsen M; Hansen SH; Mellemgaard A
Cancer Chemother Pharmacol; 2014 Aug; 74(2):349-57. PubMed ID: 24934863
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
Bonate PL; Floret S; Bentzen C
Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
[TBL] [Abstract][Full Text] [Related]
20. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
